84 related articles for article (PubMed ID: 30373860)
1. Identification of Candidate Genes Associated with Chemotherapy Resistance in Ovarian Cancer.
Zhang B; Wang L; Zhao X; Wei Y; Zhang Y
Ann Clin Lab Sci; 2018 Sep; 48(5):573-579. PubMed ID: 30373860
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis.
Wei S; Liu J; Shi Y; Zhang X; Yang Y; Song Q
Mol Med Rep; 2017 Sep; 16(3):3155-3160. PubMed ID: 28713952
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
6. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract][Full Text] [Related]
7. Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies.
Cheng L; Lu W; Kulkarni B; Pejovic T; Yan X; Chiang JH; Hood L; Odunsi K; Lin B
Gynecol Oncol; 2010 May; 117(2):159-69. PubMed ID: 20181382
[TBL] [Abstract][Full Text] [Related]
8. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
9. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM
Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968
[TBL] [Abstract][Full Text] [Related]
10. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
11. Identification of Key Genes and miRNAs in Osteosarcoma Patients with Chemoresistance by Bioinformatics Analysis.
Xie B; Li Y; Zhao R; Xu Y; Wu Y; Wang J; Xia D; Han W; Chen D
Biomed Res Int; 2018; 2018():4761064. PubMed ID: 29850522
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of NEK2 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Oncol Rep; 2014 Feb; 31(2):745-54. PubMed ID: 24337664
[TBL] [Abstract][Full Text] [Related]
13. A network-pathway based module identification for predicting the prognosis of ovarian cancer patients.
Wang X; Wang SS; Zhou L; Yu L; Zhang LM
J Ovarian Res; 2016 Nov; 9(1):73. PubMed ID: 27806724
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells.
Gao S; Zhu L; Feng H; Hu Z; Jin S; Song Z; Liu D; Liu J; Hao Y; Li X; Lin B
Tumour Biol; 2016 Sep; 37(9):12251-12262. PubMed ID: 27240592
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome.
Cai SY; Yang T; Chen Y; Wang JW; Li L; Xu MJ
J Ovarian Res; 2015 Jul; 8():50. PubMed ID: 26228058
[TBL] [Abstract][Full Text] [Related]
16. Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.
Zheng H; Zhang M; Ma S; Yang W; Xie S; Wang Y; Liu Y; Kai J; Ma Q; Lu R; Guo L
Cancer Med; 2020 Jul; 9(14):5200-5209. PubMed ID: 32441484
[TBL] [Abstract][Full Text] [Related]
17. A random forest classifier predicts recurrence risk in patients with ovarian cancer.
Cheng L; Li L; Wang L; Li X; Xing H; Zhou J
Mol Med Rep; 2018 Sep; 18(3):3289-3297. PubMed ID: 30066910
[TBL] [Abstract][Full Text] [Related]
18. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.
Fang E; Zhang X
Cancer Biomark; 2017 Dec; 21(1):373-381. PubMed ID: 29081411
[TBL] [Abstract][Full Text] [Related]
19. Neural activities are unfavorable for the prognosis of ovarian cancer through mRNA expression analysis.
Yang L; Bie L; Sun L; Yue Y
Biomark Med; 2019 Jun; 13(8):663-673. PubMed ID: 30982327
[No Abstract] [Full Text] [Related]
20. Clinical value of survivin and its underlying mechanism in ovarian cancer: A bioinformatics study based on GEO and TCGA data mining.
Li XJ; Pang JS; Li YM; Ahmed FA; He RQ; Ma J; Ma FC; Chen G
Pathol Res Pract; 2018 Mar; 214(3):385-401. PubMed ID: 29499854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
